AstraZeneca’s oral relaxin drug shows partial success in mid-stage heart-failure trial

AstraZeneca reported that its oral relaxin agonist improved cardiac function in a subset of patients enrolled in a mid-stage heart‑failure study. The trial demonstrated measurable benefits for some participants, although the response was not uniform across the entire cohort.

The findings were presented at the ESC Congress in Munich, highlighting the drug’s potential to address unmet needs in heart‑failure treatment. While the results are encouraging, the company noted that the data represent a partial success rather than a definitive breakthrough.

AstraZeneca plans to continue evaluating the therapy in further studies to confirm its efficacy and safety profile before moving toward later‑stage development.